Phase 2 Start

CGEM: Phase2_Start: A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refractory Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

Name: Phase2_Start: A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refractory Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia
Start: 2026-12-01
End: 2026-12-01

December 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2026
Company: Cullinan Therapeutics, Inc. (CGEM)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 2 Start

Phase2_Start: A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refractory Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

December 1, 2026

CGEM overview →

Company: Cullinan Therapeutics, Inc. (CGEM)

Other upcoming events for CGEM

Phase 1 StartPhase1_Start: A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid Leukemia

Oct 15, 2026

PDUFA DatePDUFA: 0001193125-26-411011

Feb 27, 2027